Form 4: Amgen Executive Sells Shares for Tax Obligations

Amgen's EVP & General Counsel, Jonathan P. Graham, disposed of 5,353 common shares to cover tax liabilities related to equity vesting.

Summary

• Jonathan P. Graham, Amgen's Executive Vice President, General Counsel, and Secretary, reported a transaction on March 16, 2026.
• Graham disposed of 5,353 shares of Amgen common stock at a price of $366.21 per share.
• This disposition was coded as 'F', indicating shares were withheld to satisfy tax obligations incident to the vesting of equity.
• Following this transaction, Graham beneficially owns 39,267 shares of Amgen common stock.
• The beneficially owned shares include 659 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are paid out in shares on a one-to-one basis according to the vesting schedule.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary transaction for tax purposes related to equity vesting, which does not reflect a change in the executive's investment sentiment.

Positives

• The transaction is a non-discretionary sale for tax withholding purposes, which is a routine event and does not necessarily reflect a change in the executive's confidence in the company.

Negatives

• The disposition of shares for tax purposes is a standard occurrence when equity awards vest and does not inherently indicate a negative outlook from the insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Amgen's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those coded 'F' for tax withholding, are common and generally not indicative of a change in an executive's confidence in the company's future. Such transactions are a standard part of equity compensation plans across the pharmaceutical and biotechnology industry.

Comparison to Industry Standards

• This type of transaction (shares withheld for tax) is a standard practice for equity compensation in publicly traded companies, including peers like Pfizer, Johnson & Johnson, and Merck.
• It aligns with typical executive compensation structures where equity awards vest and taxes are covered by selling a portion of the shares, similar to practices observed at companies such as Novartis and AstraZeneca.

Stakeholder Impact

• This routine transaction has minimal direct impact on shareholders, employees, customers, suppliers, or creditors, as it is a standard part of executive compensation and tax obligations.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax liabilities upon the vesting of equity awards. Such transactions are common and do not typically signal a change in the company's fundamentals or the executive's long-term outlook. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Amgen, AMGN, Insider Trading, Form 4, Stock Sale, Tax Withholding, Equity Compensation, Jonathan P. Graham, SEC Filing